Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide effect and action in diabetes (LEAD) trials
Follow your healthcare providers instructions for dose adjustment
Why this interaction matters: Hypoglycemia can cause shaking, sweating, dizziness, and confusion, among other symptoms
Tirzepatide may produce greater average weight loss for some individuals because it activates two hormone pathways, GLP-1 and GIP, while semaglutide targets only the GLP-1 receptor
It lowers hunger, delays stomach emptying, and increases insulin production to control blood sugar levels
Then, let it dry completely before proceeding to the next step